Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2012

Knappskog Stian, Trovik Jone, Marcickiewicz Janusz, Tingulstad Solveig, Staff Annetine C, Romundstad Pål, Hveem Kristian, Vatten Lars, Salvesen Helga B, Lønning Per E

Abstract excerpt

INTRODUCTION: The MDM2 promoter polymorphism (SNP309T > G) extends a binding site for the transcription factor Sp1 and has been linked to elevated cancer risk and/or young age at cancer diagnosis, especially in females. Recently, we reported an adjacent polymorphism (SNP285G > C). SNP285C antagonises the effect of SNP309G by reducing Sp1 binding and lowers the risk of breast and ovarian cancer. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Binding Sites
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins c-mdm2

Share to Receptors, Estrogen

Share to Sex Factors

Share to Sp1 Transcription Factor

Source

Identifiers

PMID: 22119201
DOI: 10.1016/j.ejca.2011.10.024

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.PMID 22119201Read ↗

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.Semantic proximity Read ↗

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer.Semantic proximity Read ↗

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.Semantic proximity Read ↗

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).Semantic proximity Read ↗

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.Semantic proximity Read ↗

Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.Semantic proximity Read ↗

MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.Semantic proximity Read ↗

SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers.Semantic proximity Read ↗

Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.Semantic proximity Read ↗

MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.Semantic proximity Read ↗

MDM2 SNP309 polymorphism contributes to endometrial cancer susceptibility: evidence from a meta-analysis.Semantic proximity Read ↗

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.